[Basophil activation test to follow-up of patients treated with hymenoptera venom immunotherapy: a review of current evidence].

Q3 Medicine Revista alergia Mexico Pub Date : 2023-02-01 DOI:10.29262/ram.v69i3.1135
Virginia Rodríguez-Vázquez, Sara López-Freire, Paula Méndez-Brea, María Teresa González-Fernández, Cristian Hernández-Pérez, Carmen Vidal
{"title":"[Basophil activation test to follow-up of patients treated with hymenoptera venom immunotherapy: a review of current evidence].","authors":"Virginia Rodríguez-Vázquez,&nbsp;Sara López-Freire,&nbsp;Paula Méndez-Brea,&nbsp;María Teresa González-Fernández,&nbsp;Cristian Hernández-Pérez,&nbsp;Carmen Vidal","doi":"10.29262/ram.v69i3.1135","DOIUrl":null,"url":null,"abstract":"<p><p>Hymenoptera venom immunotherapy (HVI) is a long-term effective treatment to avoid new systemic reactions in patients with Hymenoptera allergy. The sting challenge test is considered the gold standard to confirm the tolerance. However, the use of this technique is not generalized in clinical practice, being the basophil activation test (BAT), which functionally explores allergen response, an alternative that does not entail any of the provocation risks associated with the sting challenge test. This study reviews the publications that used the BAT to follow up and evaluate the success of the HVI. Studies assessing the changes between a baseline BAT before the start and BATs performed between the starting and maintenance phases of the HVI were selected. Ten articles were found, comprising information from 167 patients, of which 29% used the sting challenge test. The studies concluded the importance of evaluating the responses with submaximal allergen concentrations, which reflect basophil sensitivity, to monitor the HVI using the BAT. It was also observed that changes in the maximum response (reactivity) could not reflect the clinical status of tolerance, particularly in the initial phases of HVI.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"69 3","pages":"125-137"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista alergia Mexico","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29262/ram.v69i3.1135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Hymenoptera venom immunotherapy (HVI) is a long-term effective treatment to avoid new systemic reactions in patients with Hymenoptera allergy. The sting challenge test is considered the gold standard to confirm the tolerance. However, the use of this technique is not generalized in clinical practice, being the basophil activation test (BAT), which functionally explores allergen response, an alternative that does not entail any of the provocation risks associated with the sting challenge test. This study reviews the publications that used the BAT to follow up and evaluate the success of the HVI. Studies assessing the changes between a baseline BAT before the start and BATs performed between the starting and maintenance phases of the HVI were selected. Ten articles were found, comprising information from 167 patients, of which 29% used the sting challenge test. The studies concluded the importance of evaluating the responses with submaximal allergen concentrations, which reflect basophil sensitivity, to monitor the HVI using the BAT. It was also observed that changes in the maximum response (reactivity) could not reflect the clinical status of tolerance, particularly in the initial phases of HVI.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[嗜碱性粒细胞激活试验对膜翅目毒液免疫治疗患者的随访:现有证据的回顾]。
膜翅目蜂毒免疫治疗(HVI)是一种长期有效的治疗方法,可避免膜翅目过敏患者出现新的全身反应。刺痛挑战测试被认为是确认公差的金标准。然而,这项技术在临床实践中的应用并不普遍,因为嗜碱性粒细胞激活试验(BAT)在功能上探索了过敏原反应,这是一种不需要任何与刺痛激发试验相关的激发风险的替代方法。本研究回顾了使用BAT跟踪和评估HVI成功的出版物。选择评估开始前基线BAT和在HVI开始和维持阶段之间进行BAT之间变化的研究。发现10篇文章,包括167名患者的信息,其中29%使用刺刺激发试验。这些研究得出结论,评估反映嗜碱性粒细胞敏感性的亚最大过敏原浓度对使用BAT监测HVI的重要性。还观察到,最大应答(反应性)的变化不能反映耐受性的临床状态,特别是在HVI的初始阶段。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Revista alergia Mexico
Revista alergia Mexico Medicine-Immunology and Allergy
CiteScore
0.70
自引率
0.00%
发文量
9
审稿时长
16 weeks
期刊最新文献
[Kawasaki disease and multisystem inflammatory syndrome in children. Differences, and similarities in a pediatric center in Mexico]. [Adverse drug events in hospitalized patients: prevalence, causes and risk factors]. [Mesenchymal stem cells: Therapeutic option in ARDS, COPD, and COVID-19 patients]. [A drink with an unexpected ending... Adverse reaction by tonic water: A case report]. [Health related to quality life of patients with hereditary angioedema in Argentina. A multicenter study].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1